LENZ Therapeutics Launches Telehealth Platform for VIZZ, Boosting Patient Access
LENZ is trading near its 52-week low of $5.23 (12% above the low).
Summary
LENZ Therapeutics has launched a new telehealth prescribing option for its VIZZ eye drops, which treat presbyopia. This platform provides online evaluations, e-pharmacy fulfillment, and home delivery, aiming to remove a key barrier to access for the 128 million Americans with presbyopia. This strategic move, coupled with a national TV advertising campaign, is designed to accelerate patient awareness, access, and adoption of VIZZ. The company previously reported Q1 losses due to VIZZ commercialization investments, making this expansion of distribution critical for driving sales and offsetting those costs.
At the time of this announcement, LENZ was trading at $5.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $184.7M. The 52-week trading range was $5.23 to $50.40. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.